Charul Rathore

Dr. Charul Rathore


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2022 in Drug Delivery and Translational Research
Verified
Journal Article
Open access
PDF file
Charul RathoreCharul Rathore
Charul Rathore
CHChetna Hemrajani
Chetna Hemrajani
ASAbhishek Kumar Sharma
Abhishek Kumar Sharma
PGPiyush Kumar Gupta
Piyush Kumar Gupta
NJNiraj Kumar Jha
Niraj Kumar Jha
Murtaza TambuwalaMurtaza Tambuwala
Murtaza Tambuwala
Thymoquinone (TQ) is an antioxidant, anti-inflammatory, and hepatoprotective compound obtained from the black seed oil of Nigella sativa. However, high hydrophobicity, instability at higher pH levels, photosensitivity, and low oral bioavailability hinder its delivery to the target tissues. A self-nanoemulsifying drug delivery system (SNEDDS) was fabricated using the microemulsification technique to address these issues. Its physicochemical properties, thermodynamic stability studies, drug release kinetics, in vivo pharmacokinetics, and hepatoprotective activity were evaluated. The droplet size was in the nano-range (< 90 nm). Zeta potential was measured to be −11.35 mV, signifying the high stability of the oil droplets. In vivo pharmacokinetic evaluation showed a fourfold increase in the bioavailability of TQ-SNEDDS over pure TQ. Furthermore, in a PCM-induced animal model, TQ-SNEDDS demonstrated significant (p < 0.05) hepatoprotective activity compared to pure TQ and silymarin. Reduction in liver biomarker enzymes and histopathological examinations of liver sections further supported the results. In this study, SNEDDS was demonstrated to be an improved oral delivery method for TQ, since it potentiates hepatotoxicity and enhances bioavailability. Graphical abstract

1 April 2017 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
PNPoonam Negi
Poonam Negi
MAMadhur Aggarwal
Madhur Aggarwal
GSGajanand Sharma
Gajanand Sharma
Charul RathoreCharul Rathore
Charul Rathore
Gaurav SharmaGaurav Sharma
Gaurav Sharma
OKO.P. Katare
O.P. Katare

23 April 2024 in Therapeutic Delivery
Verified
Journal Article
Closed access
MDManoj Dalabehera
Manoj Dalabehera
Charul RathoreCharul Rathore
Charul Rathore
ARAnkit Rathee
Ankit Rathee
URUma Ranjan
Uma Ranjan
Despite having current advanced therapy, vulvovaginal candidiasis (VVC) remains a common yet debated healthcare-associated topic worldwide due to multi-drug resistance Candida species. In our revie... Plain language summary There is a type of fungi called Candida that is responsible for infections like vulvovaginal candidiasis in the human vagina. Due to resistance of currently available antifun... Graphical abstract

23 November 2024 in Current Treatment Options in Infectious Diseases
Verified
Journal Article
Closed access
PDF file
AKAlka Kumari
Alka Kumari
NBNeha Bajwa
Neha Bajwa
TATamana
Tamana
SASumel Ashique
Sumel Ashique
Dr. Himanshu SharmaDr. Himanshu Sharma
Dr. Himanshu Sharma
PSPreet Amol Singh
Preet Amol Singh

1 December 2024 in Recent Advances in Drug Delivery and Formulation
Verified
Journal Article
Closed access
PDF file
VSVarun Singh
Varun Singh
SVSamar Vihal
Samar Vihal
RRRupali Rana
Rupali Rana
Charul RathoreCharul Rathore
Charul Rathore
: Medical cannabis has potential therapeutic benefits in managing pain, anxiety, depression, and neurological and movement disorders. Phytocannabinoids derived from the cannabis plant are responsible for their pharmacological and therapeutic properties. However, the complexity of cannabis components, especially cannabinoids, poses a challenge to effective medicinal administration. Even with the increasing acceptance of cannabis-based medicines, achieving consistent bioavailability and targeted distribution remains difficult. Conventional administration methods are plagued by solubility and absorption problems requiring innovative solutions. After conducting a thorough review of research papers and patents, it has become evident that nanotechnology holds great promise as a solution. The comprehensive review of 36 research papers has yielded valuable insights, with 7 papers reporting enhanced bioavailability, while others have focused on improvements in release, solubility, and stability. Additionally, 19 patents have been analyzed, of which 7 specifically claim enhanced bioavailability, while the remaining patents describe various formulation methods. These patents outline effective techniques for encapsulating cannabis using nanocarriers, effectively addressing solubility and controlled release. Studies on the delivery of cannabis using nanocarriers focus on improving bioavailability, prolonging release, and targeting specific areas. This synthesis highlights the potential of nanotechnology to enhance cannabis therapies and pave the way for innovative interventions and precision medicine.

1 January 2025 in Current Drug Delivery
Verified
Journal Article
Closed access
PDF file
SVSamar Vihal
Samar Vihal
SPSwati Pundir
Swati Pundir
Charul RathoreCharul Rathore
Charul Rathore
ULUma Ranjan Lal
Uma Ranjan Lal
GGGaurav Gupta
Gaurav Gupta
PNPoonam Negi
Poonam Negi
Background: The therapeutic effect of NS oil in mild to moderate psoriasis is limited owing to low play load of thymoquinone (<15 %w/w), irritation, dripping, low viscosity and thus, less contact time on the lesions. Aims:: This study aimed at developing and characterizing the ethanolic vesicular hydrogel system of Nigella sativa (NS) oil (NS EV hydrogel) for the enhancement of anti-psoriatic activity. Objective: The objective of this study was to develop NS EV hydrogel and evaluate its anti-psoriatic activity. Methods: The identification and quantification of TQ content in different NS seed extracts and marketed oil were measured by an HPTLC method using n-hexane and ethyl acetate as solvent systems. Preparation of ethanolic vesicles (EVs) was performed by solvent injection method, while its antipsoriatic activity was evaluated employing an Imiquad (IMQ)-induced plaque psoriasis animal model. Results: A compact HPTLC band was obtained for TQ at an Rf value of 0.651. The calibration plot was linear in the range of 1-10 μg/spot, and the correlation coefficient of 0.990 was indicative of good linear dependence of peak area on concentration. From the different NS sources, the high TQ content was obtained in the marketed cold press oil, i.e., 1.45±0.08mg/ml. Out of various NS oilloaded EVs, the F6 formulation revealed the smallest particle size (278.1nm), with log-normal size distribution (0.459) and adequate entrapment efficiency. A non-uniform shape was observed in the transmission electron microscopy. The viscosity of F6 formulation hydrogel was 32.34 (Pa·s), which exhibited plastic behavior. In vivo, efficacy studies demonstrated decreased inflammation of the epidermis and dermis and a marked decrease in the levels of IL-17 by NS EV hydrogel compared to plain NS oil and standard drugs (Betamethasone and Dr. JRK Psorolin Oil). Conclusion: It may be concluded from the findings that NS-loaded EV gel was as good as betamethasone cream but more efficacious than the other treatments.